Bicyclic pyrrole derivatives

Details Bicyclic pyrrole derivatives Bicyclic pyrrole derivatives

2008-05-28

2009-10-13

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S280000

Reexamination Certificate

active

07601728

ABSTRACT:
Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I)wherein the solid line and dotted line between A1and A2represents a double bond (A1═A2) or the like; A1is C(R4) or the like; A2is nitrogen atom or the like; R1is hydrogen atom, optionally substituted alkly group, or the like; R2is hydrogen atom, optionally substituted alkyl group, or the like; R3is hydrogen atom, halogen atom, or the like; R4is hydrogen atom, hydroxyl, halogen atom, or the like; and Y is a group represented by the general formula (A) or the like; (A)[wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R6or substituted with one or two R6's which are each independently halogen atom or the like.]

REFERENCES:
patent: 2002/0198205 (2002-12-01), Himmelsbach et al.
patent: 2003/0105077 (2003-06-01), Kanstrup et al.
patent: 2003/0199528 (2003-10-01), Kanstrup et al.
patent: 2004/0116328 (2004-06-01), Yoshikawa et al.
patent: 2003-300977 (2003-10-01), None
patent: 03/004496 (2003-01-01), None
patent: 03/024965 (2003-03-01), None
patent: 03/104229 (2003-12-01), None
patent: 2007/071738 (2007-06-01), None
R.A. Pederson, et al., “Improved Glucode Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl peptidase IV Inhibitor Isoleucine Thiazolidide”,Diabetes, vol. 47, 1998, pp. 1253-1258.
Cellular Peptidases in Immune Functions and Diseases 2, Edited by J. Langer and S. Ansorge, Kluwer Acadamic/Plenum Publishers, 2000, pp. 111-122, 336-338 and 522.
L. B. Knudsen and Lone Pridal, “Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagons-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor”, European Journal of Pharmacology, vol. 318, 1996, pp. 429-435.
T.J. Kieffer, et al., “Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV”,Endocrinology, vol. 136, No. 8, 1995, pp. 3585-3596.
U.S. Appl. No. 12/144,430 to Hiroyuki Nakahira, et al., filed Jun. 23, 2008.

Affiliated with

Also associated with

Rating

Bicyclic pyrrole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic pyrrole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic pyrrole derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132556